A randomized study to assess the effect on response rate of MabThera (rituximab) added to a standard chemotherapy, Bendamustine or Chlorambucil, in patients with Chronic Lymphocytic Leukemia.

Next Previous
Trial Profile

A randomized study to assess the effect on response rate of MabThera (rituximab) added to a standard chemotherapy, Bendamustine or Chlorambucil, in patients with Chronic Lymphocytic Leukemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2015

At a glance

  • Drugs Rituximab (Primary) ; Bendamustine; Chlorambucil
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms MaBLe; RiBECCA
  • Sponsors Roche

    • Most Recent Events

    • 30 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 13 Jan 2014 Planned End Date changed from 1 May 2014 to 1 Apr 2014 as per ClinicalTrials.gov record.
    • 07 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top